Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL

C. Tam, J. Pinilla-Ibarz, CG. Castillo, AC. Fenili, K. Huntley, V. Karakus, M. Mattar, MA. Miroli, C. Moura, M. Pavlovsky, F. Piotrowski, M. Šimkovič, S. Stilgenbauer

. 2023 ; 7 (22) : 6819-6828. [pub] 2023Nov28

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000601

The Virtual Opinions poll Independent Centered on CLL patients' Experience (VOICE) evaluated patients' knowledge about chronic lymphocytic leukemia (CLL), their perspectives on diagnosis and treatment, and their unmet needs. Clinicians and patient advocacy group representatives developed and distributed the survey from March through December 2022 in 12 countries, and 377 patients with ≥1 line of previous CLL treatment responded from Europe, Latin America, the United States, Australia, Egypt, and Turkey. A majority of them (90%; 336/374) relied on their physicians for information regarding CLL and treatment. If at high risk, respondents prefer oral medications to intravenous (78%; 232/296), fixed duration treatment over treatment until progression (69%; 185/270), outpatient over inpatient treatments (91%; 257/283). Over three-fourths of respondents (78%; 286/368) wanted to be involved in treatment decisions, but a minority actually participated (44%; 138/313). COVID-19 vaccinations were widely available (97%; 273/281), but one-fifth (19%; 63/331) were unaware that CLL increases vulnerability to infections. Most patients' physicians explained their treatment options (84%; 297/355), and 90% (271/301) understood their treatment. Notably, >10% would continue treatment normally if they experienced cardiac problems or arrhythmias, whereas 23% would consider stopping treatment if they developed skin cancer. Treatment-associated side effects affected 27% to 43% of patients. These results in a global patient population highlight gaps in patients' knowledge of risk groups, their susceptibility to infections including COVID, and the side effects of common treatments. Such knowledge can guide the appropriate targeting of patient education initiatives by clinicians, advocates, and policymakers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000601
003      
CZ-PrNML
005      
20240213093259.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2023010879 $2 doi
035    __
$a (PubMed)37722356
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tam, Constantine $u Lymphoma Service, Alfred Hospital and Monash University, Melbourne, Australia
245    10
$a Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL / $c C. Tam, J. Pinilla-Ibarz, CG. Castillo, AC. Fenili, K. Huntley, V. Karakus, M. Mattar, MA. Miroli, C. Moura, M. Pavlovsky, F. Piotrowski, M. Šimkovič, S. Stilgenbauer
520    9_
$a The Virtual Opinions poll Independent Centered on CLL patients' Experience (VOICE) evaluated patients' knowledge about chronic lymphocytic leukemia (CLL), their perspectives on diagnosis and treatment, and their unmet needs. Clinicians and patient advocacy group representatives developed and distributed the survey from March through December 2022 in 12 countries, and 377 patients with ≥1 line of previous CLL treatment responded from Europe, Latin America, the United States, Australia, Egypt, and Turkey. A majority of them (90%; 336/374) relied on their physicians for information regarding CLL and treatment. If at high risk, respondents prefer oral medications to intravenous (78%; 232/296), fixed duration treatment over treatment until progression (69%; 185/270), outpatient over inpatient treatments (91%; 257/283). Over three-fourths of respondents (78%; 286/368) wanted to be involved in treatment decisions, but a minority actually participated (44%; 138/313). COVID-19 vaccinations were widely available (97%; 273/281), but one-fifth (19%; 63/331) were unaware that CLL increases vulnerability to infections. Most patients' physicians explained their treatment options (84%; 297/355), and 90% (271/301) understood their treatment. Notably, >10% would continue treatment normally if they experienced cardiac problems or arrhythmias, whereas 23% would consider stopping treatment if they developed skin cancer. Treatment-associated side effects affected 27% to 43% of patients. These results in a global patient population highlight gaps in patients' knowledge of risk groups, their susceptibility to infections including COVID, and the side effects of common treatments. Such knowledge can guide the appropriate targeting of patient education initiatives by clinicians, advocates, and policymakers.
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x terapie $x farmakoterapie $7 D015451
650    _2
$a pacienti ambulantní $7 D010045
650    12
$a lékaři $7 D010820
650    _2
$a trvání terapie $7 D000081206
651    _2
$a Spojené státy americké $7 D014481
651    _2
$a Austrálie $x epidemiologie $7 D001315
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pinilla-Ibarz, Javier $u Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
700    1_
$a Castillo, Carolina G $u Department of Hematology, Hospital Star Medica Lomas Verdes, Mexico City, Mexico $1 https://orcid.org/0000000170793091
700    1_
$a Fenili, Ana Cristina $u Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
700    1_
$a Huntley, Kathryn $u Health Services, Leukaemia Foundation, Brisbane, Australia $1 https://orcid.org/0000000317229920
700    1_
$a Karakus, Volkan $u Department of Hematology, Antalya Research and Training Hospital, Antalya, Turkey
700    1_
$a Mattar, Mervat $u Hematology Unit, Department of Internal Medicine, Cairo University, Giza, Egypt
700    1_
$a Miroli, Miguel A $u Hospital Médico Policial Churruca-Visca, Buenos Aires, Argentina
700    1_
$a Moura, Catherine $u Associaçäo Brasileira De Linfoma E Leucemia, São Paulo, Brazil
700    1_
$a Pavlovsky, Miguel $u Department of Hematology, Fundacion para Combatir la Leucemia, Buenos Aires, Argentina $1 https://orcid.org/0000000345613153
700    1_
$a Piotrowski, Fernando $u Asociación Leucemia Mieloide de Argentina, Buenos Aires, Argentina
700    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic $1 https://orcid.org/0000000303315334 $7 xx0117538
700    1_
$a Stilgenbauer, Stephan $u Department of Internal Medicine III, University of Ulm, Ulm, Germany
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 7, č. 22 (2023), s. 6819-6828
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37722356 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093256 $b ABA008
999    __
$a ok $b bmc $g 2049325 $s 1210295
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 7 $c 22 $d 6819-6828 $e 2023Nov28 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options